Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Entrada Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 38 | 33 | −5 |
| Shares | 24.8M | 24.5M | −261.7K (−1.1%) |
| Value | $301.8M | $386.4M | +$84.5M (+28.0%) |
New holders (4)
Institutions that held Entrada Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Invesco Ltd. | 95,209 | $1.50M | 0.00% |
| Fred Alger Management, LLC | 17,955 | $283.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,508 | $40.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 198 | $3.12K | 0.00% |
Sold out (9)
Institutions that held Entrada Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| CHI Advisors LLC | 163,496 | $1.99M |
| Suvretta Capital Management, LLC | 106,000 | $1.29M |
| Millennium Management LLC | 76,498 | $932.0K |
| Ergoteles LLC | 18,807 | $229.0K |
| Citadel Advisors LLC | 12,947 | $158.0K |
| Old Well Partners, LLC | 12,700 | $155.0K |
| UBS Group AG | 597 | $8.00K |
| New York State Common Retirement Fund | 109 | $1.00K |
| Credit Suisse AG | 6 | $0 |